Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with EGFR mutation, little is known about the efficacy of EGFR-TKIs according to different treatment timings.

          Related collections

          Author and article information

          Journal
          Cancer Chemother. Pharmacol.
          Cancer chemotherapy and pharmacology
          Springer Nature
          1432-0843
          0344-5704
          Jan 2015
          : 75
          : 1
          Affiliations
          [1 ] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86, Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea.
          Article
          10.1007/s00280-014-2631-5
          25422153

          Comments

          Comment on this article